- Trials with a EudraCT protocol (127)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
127 result(s) found for: Pulmonary edema.
Displaying page 4 of 7.
EudraCT Number: 2004-004801-11 | Sponsor Protocol Number: 04-081 | Start Date*: 2005-02-14 |
Sponsor Name:Zealand Pharma A/S | ||
Full Title: A Phase II, Multicenter, Double-Blind, Efficacy, Safety, and Tolerability Study of ZP120 Administered as Short Term I.V. Infusion as Add-On Therapy in Patients with Subacute Decompensated Chronic H... | ||
Medical condition: Subacute decompensated chronic heart failure NYHA Class III-IV | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DK (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2012-001642-17 | Sponsor Protocol Number: AMB116457 | Start Date*: 2013-04-26 | |||||||||||
Sponsor Name:GlaxoSmithKline, S.A. | |||||||||||||
Full Title: An open-label extension study of the long-term safety, tolerability and efficacy of ambrisentan in subjects with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) | |||||||||||||
Medical condition: Subjects with inoperable chronic thromboembolic pulmonary hypertension (CTEPH). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) AT (Completed) DE (Completed) GB (Prematurely Ended) CZ (Prematurely Ended) NL (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-002632-75 | Sponsor Protocol Number: CLI-050000-04 | Start Date*: 2020-07-08 |
Sponsor Name:CHIESI FARMACEUTICI S.p.A | ||
Full Title: Multicenter, open-label, randomised trial to assess the efficacy and tolerability of poractant alfa (porcine surfactant, Curosurf®) in hospitalized patients with SARS-COV-19 acute respiratory distr... | ||
Medical condition: patients with SARS-COV-19 acute respiratory distress syndrome (ARDS) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) IT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2020-002322-85 | Sponsor Protocol Number: KAN0006 | Start Date*: 2020-07-02 |
Sponsor Name:Kancera AB | ||
Full Title: KAND567 Versus Placebo in Subjects Hospitalized with COVID-19. A Phase II, Randomized, 2-Arm Parallel-Group, Double-blind Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics. | ||
Medical condition: Acute respiratory distress syndrome (ARDS) in COVID-19 infection | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) DK (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2020-001302-30 | Sponsor Protocol Number: ACOVACT | Start Date*: 2020-04-15 | ||||||||||||||||||||||||||
Sponsor Name:Medical University of Vienna | ||||||||||||||||||||||||||||
Full Title: A multicenter, randomized, active controlled, open label, platform trial on the efficacy and safety of experimental therapeutics for patients with COVID-19 (caused by infection with severe acute re... | ||||||||||||||||||||||||||||
Medical condition: Infection with SARS-COV-2 (=COVID-19) | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: AT (Prematurely Ended) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2004-002732-25 | Sponsor Protocol Number: 0105 | Start Date*: 2006-02-01 |
Sponsor Name:Geir Øystein Andersen, Department of Cardiology, Ulleval University Hospital | ||
Full Title: Safety and efficacy of levosimendan in patients with acute myocardial infarction complicated by symptomatic left ventricular failure | ||
Medical condition: Patients with acute myocardial infarction developing acute heart failure after primary PCI (percutaneus coronary intervention). Some patients in a predefined subgroup are categorized as patients in... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NO (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2006-001637-18 | Sponsor Protocol Number: CKI- 302 | Start Date*: 2006-11-13 | |||||||||||
Sponsor Name:NovaCardia Inc (wholly owned subsidiary of Merck & Co. Inc) | |||||||||||||
Full Title: A multicentre, randomised, double-blind, placebo-controlled study of the effects of KW-3902 Injectable Emulsion on heart failure signs and symptoms and renal function in subjects with acute heart f... | |||||||||||||
Medical condition: Patients being admitted to hospital for acute heart failure (AHFS) with volume overload and renal impairment. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) FI (Completed) CZ (Completed) BE (Completed) DK (Prematurely Ended) GB (Completed) HU (Completed) DE (Completed) NL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000486-37 | Sponsor Protocol Number: CHF201701 | Start Date*: 2019-03-27 |
Sponsor Name:Heart Initiative | ||
Full Title: STRONG-HF: Safety, Tolerability and efficacy of Rapid Optimization, helped by NT-proBNP testing, of Heart Failure therapies | ||
Medical condition: Acute Heart Failure | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) HR (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-005059-35 | Sponsor Protocol Number: TMP-2204-2021-47 | Start Date*: 2022-01-25 | ||||||||||||||||
Sponsor Name:F4-Pharma GmbH i.G. | ||||||||||||||||||
Full Title: Potential of FX06 to improve disease severity in Acute Respiratory Distress Syndrome patients (Ixion 2.0) | ||||||||||||||||||
Medical condition: Acute Respiratory Distress Syndrome (ARDS) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Trial now transitioned) ES (Ongoing) LT (Trial now transitioned) PT (Prematurely Ended) IT (Prematurely Ended) NL (Completed) RO (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-001407-37 | Sponsor Protocol Number: CKI- 301 | Start Date*: 2007-06-20 | |||||||||||
Sponsor Name:NovaCardia Inc (wholly owned subsidiary of Merck & Co. Inc) | |||||||||||||
Full Title: A multicentre, randomised, double-blind, placebo-controlled study of the effects of KW-3902 Injectable Emulsion on heart failure signs and symptoms and renal function in subjects with acute heart f... | |||||||||||||
Medical condition: Patients being admitted to hospital for acute heart failure (AHFS) with volume overload and renal impairment. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) CZ (Completed) HU (Completed) IT (Completed) NL (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-006337-19 | Sponsor Protocol Number: R5381-HF-2159 | Start Date*: 2022-06-08 | |||||||||||
Sponsor Name:Regeneron Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of REGN5381, an NPR1 Agonis... | |||||||||||||
Medical condition: Heart Failure | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Prematurely Ended) HU (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-003531-21 | Sponsor Protocol Number: Debio 0614-202 | Start Date*: 2009-05-05 | |||||||||||
Sponsor Name:DEBIOPHARM S.A. | |||||||||||||
Full Title: A multicenter, randomized, double-blind, placebo-controlled parallel-group phase IIb study of the safety and efficacy of istaroxime over 24 hours at three doses in acute decompensated heart failure... | |||||||||||||
Medical condition: acute decompensated heart failure | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) LT (Prematurely Ended) PL (Prematurely Ended) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-003153-28 | Sponsor Protocol Number: ALN-TTRSC02-003 | Start Date*: 2019-12-23 | |||||||||||
Sponsor Name:Alnylam Pharmaceuticals, Inc. | |||||||||||||
Full Title: HELIOS-B: A Phase 3 Global, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Clinical Outcomes, Efficacy and Safety of Vutrisiran in Patients with Transthyretin Amyloidosis with C... | |||||||||||||
Medical condition: Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LV (Completed) PT (Trial now transitioned) FR (Trial now transitioned) HU (Trial now transitioned) SI (Completed) NO (Trial now transitioned) IE (Trial now transitioned) LT (Trial now transitioned) ES (Ongoing) AT (Trial now transitioned) DK (Trial now transitioned) DE (Trial now transitioned) GB (GB - no longer in EU/EEA) PL (Trial now transitioned) NL (Trial now transitioned) HR (Trial now transitioned) CZ (Trial now transitioned) IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-021572-29 | Sponsor Protocol Number: AMB114588 | Start Date*: 2010-11-23 | |||||||||||||||||||||||||||||||
Sponsor Name:GlaxoSmithKline Research & Development, Ltd | |||||||||||||||||||||||||||||||||
Full Title: An open-label, long term extension study for treatment of pulmonary arterial hypertension in paediatric patients aged 8 years up to 18 years who have participated in AMB112529 and in whom continued... | |||||||||||||||||||||||||||||||||
Medical condition: Pulmonary Arterial Hypertension | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: GR (Prematurely Ended) DE (Completed) NL (Ongoing) ES (Completed) HU (Completed) IT (Completed) FR (Completed) | |||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2010-019547-19 | Sponsor Protocol Number: AMB112529 | Start Date*: 2010-07-16 | |||||||||||||||||||||||||||||||
Sponsor Name:GlaxoSmithKline Research & Development, Ltd | |||||||||||||||||||||||||||||||||
Full Title: A randomized, open label study comparing safety and efficacy parameters for a high and a low dose of ambrisentan (adjusted for body weight) for the treatment of pulmonary arterial hypertension in ... | |||||||||||||||||||||||||||||||||
Medical condition: Pulmonary Arterial Hypertension | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: GR (Prematurely Ended) NL (Completed) HU (Completed) DE (Completed) ES (Completed) FR (Completed) IT (Completed) Outside EU/EEA | |||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-006056-37 | Sponsor Protocol Number: 1160.143 | Start Date*: 2013-09-05 | |||||||||||
Sponsor Name:Hamilton Health Sciences Corporation | |||||||||||||
Full Title: A large, international, randomized, placebo-controlled trial to assess the impact of dabigatran (a direct thrombin inhibitor) and omeprazole (a proton-pump inhibitor) in patients suffering myocardi... | |||||||||||||
Medical condition: MINS (myocardial injury after noncardiac surgery) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) IT (Completed) PT (Completed) ES (Completed) GB (Completed) AT (Completed) DE (Prematurely Ended) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-017082-39 | Sponsor Protocol Number: Bay 58-2667 / 14836 | Start Date*: 2010-02-01 | |||||||||||
Sponsor Name:Bayer Healthcare AG | |||||||||||||
Full Title: A Placebo Controlled, Randomized, Double-Blind, Fixed-dose, Multicenter, Phase IIb Study to Investigate the Efficacy and Tolerability of BAY 58-2667 (50 μg/h, 100 μg/h, 150 μg/h) Given Intravenousl... | |||||||||||||
Medical condition: Acute Decompensated Chronic Congestive Heart Failure (ADHF) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Prematurely Ended) IE (Prematurely Ended) ES (Prematurely Ended) DE (Prematurely Ended) FR (Completed) GB (Prematurely Ended) IT (Prematurely Ended) CZ (Prematurely Ended) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-003611-37 | Sponsor Protocol Number: PREVENT-CINHF | Start Date*: 2011-10-28 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA MAGGIORE DELLA CARITA' DI NOVARA | |||||||||||||
Full Title: PRevEntion of cardiac and Vascular pEriprocedural complications in patients undergoiNg coronary angiography or angioplasTy: hydratation vs carbonates to prevent Contrast-Induced Nephropathy in pati... | |||||||||||||
Medical condition: Patients undergoing coronary angiography or angioplasty | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-004602-86 | Sponsor Protocol Number: | Start Date*: 2005-11-21 |
Sponsor Name:Medical University of Vienna | ||
Full Title: A comparison of crystalloids vs. colloids for intraoperative goal-directed fluid management | ||
Medical condition: Fluid optimization has been considered as major contributor to improved oxygen delivery, and thus improved outcome in patients. Hypovolemia has been associated with significant increases in morbid... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-004217-18 | Sponsor Protocol Number: glutamine 001 | Start Date*: 2007-02-06 | |||||||||||
Sponsor Name:Leiden University Medical Center | |||||||||||||
Full Title: The Impact of glutamine suppletion on outcome in patients undergoing high-risk cardiothoracic surgery. | |||||||||||||
Medical condition: Infectious complications after high-risk cardiothoracic surgery. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
